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INTRAVENOUS injection into rats of immune complexes
(IC) prepared in 5 x antigen excess rapidly induces annu-
lar bands of vascular congestion and transmural haemor-
rhage producing a striped appearance of the small intes-
tine. Indirect evidence suggested a major role for PAF in
the induction of lesions. In the present study, we showed
that blood and leukocyte levels of PAF were elevated in
most rats injected 10 min earlier with sufficient IC to
induce lesions of3+ to 4+ intensity. There was no signifi-
cant difference in the number of rats with elevated plasma
levels of PAF. The possibility that changes in blood PAF
levels might be mirrored at sites closer to the lesions was
considered. The overall effect ofPAF on the small intestine
of the rats is to induce stasis of flow; the precise target of
PAF in mediating this effect is unknown.
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Introduction
Immune complex induced enteropathy refers to
lesions of the small intestine which develop within
minutes of the intravenous injection of immune
complexes (IC) into normal rats. The lesions
consist of annular bands of hyperaemia alternating
with nonhyperaemic bands, causing a striped
appearance. Histologically, mild lesions are accom-
panied by vascular congestion and mucosal oedema;
severe lesions are haemorrhagic throughout the
intestinal wall and show epithelial necrosis and
sloughing of the tips of villi.
Because platelet activating factor (PAF) appears
to be a major mediator of reactions elicited by IC2
and because lesions induced by PAF share some
characteristics with those induced by IC,3’4 we
previously tested the effect of dietary manipulations
that limit the availability of PAF and of three
different PAF receptor antagonists,
6 on the develop-
ment of lesions. Rats fed a diet supplemented with
fish fat had a significantly lower lesional score
compared to those on a beef fat supplemented diet.
PAF receptor antagonists were able to completely
or partially inhibit IC induced small intestinal
lesions suggesting that PAF is a major mediator of
IC induced enteropathy. In the present experi-
ments, we utilized a newly developed radio-
immunoassay to measure PAF levels in blood,
plasma and leukocytes of rats undergoing IC
induced intestinal lesions.
Methods
Animals: Male Sprague-Dawley rats weighing
125-250 g were obtained from Taconic Farms,
Germantown, New York and were maintained in
accordance with the guidelines in NIH publication
85-23. Experimental protocols were approved by
the Subcommittee on Animal Care, Committee on
Research, Massachusetts General Hospital. Animals
were fed rat chow devoid of cow’s milk proteins.
Preparation of antisera and immune complexes: The
preparation of antisera and IC has been described
in detail. 1’7 Under ether anaesthesia, rats were
injected with BSA emulsified in complete Freund’s
adjuvant and were twice reinjected with BSA in
incomplete Freund’s adjuvant. IC were prepared in
5 x antigen excess. The lesions, which developed
within 10 min of the injection of IC in all four
segments of the small intestine, were scored as
reported. ’6 The composite lesional score represent-
ing the sum of the scores of the four segments was
determined and divided by four so that the resulting
numbers correspond to the conventional 0 to 4+
scoring system. The dose of IC selected for the
present study produced lesions of 3+ to 4+
severity.
Measurement of PAF in blood, plasma and leukocytes: Ten
minutes after the intravenous injection of IC, rats
were anaesthetized with ether and blood was
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obtained by cardiac puncture. PAF was extracted
as specified in the manual accompanying the
[12sI]-PAF RIA kit (NEK-062, Dupont/New
England Nuclear); siliconized glassware was used
throughout. In brief, 2 ml blood was transferred
into a glass tube containing 2 ml 20% acetic acid,
and 10 1 of [3H]-PAF (approx 2000 cpm) was
added and the mixture vortexed for several seconds.
Thereafter, 4 ml 10% acetic acid was added and the
suspension vortexed for 10 s. The mixture was
centrifuged at 15000 x g for 45 min, the
supernatent was retained. One ml glacial acetic acid
was added to the precipitate and the mixture was
vortexed vigorously; 9 ml double distilled H20
(which was used throughout the assay) was added,
the mixture vortexed and centrifuged as above for
30 min. The combined supernatants were applied to
200 mg Bond-Elut columns (Analytichem Interna-
tional, Harbor City, CA, USA) pre-treated by
successive washing with methanol, water and 10%
acetic acid. After loading, the column was treated
three times with ethylacetate to remove acetic acid,
lipids and water, and was eluted with methanol. The
eluate was combined with H20 and chloroform in
a final ratio of chloroform/methanol/water 1:1:0.9.
The suspension was allowed to separate into two
phases; the bottom phase (chloroform) was
recovered, evaporated to dryness and stored. The
powder was reconstituted in 1.0ml of 50mM
sodium citrate buffer pH 6.3. Thereafter, the sample
was treated exactly as specified by the manufacturer
of the PAF RIA kit.
To obtain plasma, 2.0 ml blood was drawn into
a heparinized syringe, cooled immediately in a test
tube at 0C and promptly centrifuged at 500 x g
for 10 min at 4C. Plasma, 0.5 ml, was mixed with
8.5 ml of cold PBS, and 9.0 ml 20% acetic acid
containing 10 #1 [3H]-PAF was added and the
mixture vortexed repeatedly for 15min. The
mixture was centrifuged at 500 x g for 15 min,
the supernatant was recovered and applied
to a Bond-Elut column as described above.
To obtain leukocytes, 2.0 ml heparinized blood
was promptly cooled as above, centrifuged at 800 x
g for 10 min at 4C, the buffy coat removed and
recentrifuged in a Wintrobe tube at 800 x g for 10
min. The buffy coat was again recovered, washed
with 2.0ml cold PBS and recentrifuged. The
pelleted WBC were suspended in 2.0 ml PBS, and
2.0 ml 20% acetic acid was added together with
10 #1 [3H]-PAF and the mixture vortexed. Four
millitres of 10% acetic acid was added, mixed and
centrifuged at 12 000 x g for 45 min. The super-
natant was retained and the precipitate treated as
described for blood. The combined supernatants
were applied to Bond-Elute columns. Because of
the different processing required, blood, plasma and
leukocytes were obtained from separate animals.
The PAF RIA is a competitive antigen binding
assay in which natural PAF and radiolabelled PAF
compete for a limited number of antibody binding
sites. The assay was performed as recommended by
the manufacturer. The antibody is reported not to
react with arachidonic acid, prostaglandin FI=,
phosphatidylcholine and phosphotidylethanolamine
and lyso-PAF.
For results to be accepted, at least 45, 70 and 30%
of the [3H]-PAF had to be recovered from each
blood, plasma and WBC sample, respectively. The
results reported herein were corrected for recovery.
In addition, plasma values per ml blood were
corrected for change in haematocrit which
accompanies injection of IC. 1’2
Statistical methods: Control values were compared by
the 2 method
8 with those obtained at 10 min and
60min; 10min and 60min values were also
compared.
Results
Blood levels of PAF were measured in controls
and in rats injected 10 and 60 min earlier with
sufficient IC to induce lesions of 3+ to 4+
intensity. Among rats bled at 10 min after IC, there
were significantly more animals with blood levels
greater than 2.5 ng per ml compared to either the
controls (p < 0.005) or animals bled 60 min after IC
(p < 0.01). There was no significant difference in
the number of rats with blood levels greater than
2.5 ng/ml at 60min compared to the controls
(Fig 1).
Although measurement of PAF in plasma
showed more animals to have values greater than
2.5 ng/ml at 10 min compared to controls or rats
bled 60min after IC, there was no significant
difference in the number of animals with values
greater than 2.5 ng/ml among controls, or rats bled
at 10 or 60 min after IC (Fig 2).
The concentration of PAF in leukocytes from
1 mL of blood was _>0.85ng in one of eight
controls, seven of nine rats bled 10 min after IC and
three of seven rats bled 60 min after IC. There were
significantly more rats with such values at 10 min
compared to controls (p < 0.01) or rats bled at
60 min after IC (p < 0.05). There was no significant
difference in the number of animals with >_ 0.85 ng
PAF at 60 min compared to the control group
(Fig 3).
Discussion
Elucidation of the role of PAF in immune
complex-induced injury was greatly facilitated by
the introduction of specific PAF receptor antagon-
ists. Studies performed with the PAF receptor
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FIG. 1. Blood levels of PAF in control rats and rats injected 10 and 60 min
earlier with sufficient immune complexes (IC) to induce lesions of
3+ to 4+ intensity. At 10 min, there were significantly more rats with
blood levels > 2.5 ng/ml compared to control or rats bled at 60 min.
antagonist L-652,731 by Doebber et al. showed that
PAF is an important mediator of immune complex
induced hypotension and vascular permeability and
a minor mediator of immune complex induced
lysosomal hydrolase release in the rat. The liver was
Control 10’ 60’
Time (min)
FIG. 2. Plasma levels of PAF in control rats and rats injected 10 and
60 min earlier with IC. There was no significant difference in animals with
values greater than 2.5 ng/ml among the three groups. *Values reflect the
concentration of PAF in plasma from ml of blood and corrected for the
change in haematocrit that follows injection of IC.
identified as the probable major site for PAF
production in response to administration of IC.
Based on studies performed with the same PAF
receptor antagonist, Warren et al. showed that
addition of L-652,731 to the antibody used to
induce reverse passive Arthus reactions in the rat,
significantly attenuated IC-induced vasculitis.
9 They
suggested that PAF contributes to 1C induced
vascular injury by interacting with PAF receptors
on neutrophils.
9 Camussi et al. also found that a
different PAF receptor antagonist, SRI 63072,
inhibited the inflammatory injury induced by the
in situ formation of IC in the renal glomerulus and
skin of the rat.1 As mentioned above, prior
experience with the same experimental model
as used herein showed that three different PAF
receptor antagonists completely or partially in-
hibited IC induced enteropathy in the rat.
6 Taken
together, these reports strongly link PAF to IC-
induced inflammation in the rat.
Limited information is available on changes in
blood levels of PAF in response to the administra-
tion of IC in any species. In the rabbit, an increase
in circulating PAF was detected using the rabbit
platelet aggregation test; maximal values were
obtained 5-10 min after administration of IC.
1 In
the rat, the blood level ofPAF in animals subjected
to unilateral glomerulonephritis induced by in situ
formation of IC was 10.5 --/-_ 3.8 ng/ml compared
to control values of 2.5 _-/- 0.8 ng/ml.
2 These levels
are much higher than were found in the blood of
humans,2’3 rabbits
1 or dogs.
4 The extent to which




FIG. 3. Concentration of PAF in leukocytes from control rats and rats
injected 10 and 60 min earlier with IC. At 10 min, there were significantly
more rats with >0.85 ng PAF in leukocytes from ml of blood compared
to controls or rats bled at 60 min. *Values reflect the concentration of
PAF in leukocytes from ml blood.
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to the blood levels of PAF found in the rat has not
been determined. It is likely that the complexity of
bioassays for PAF has hindered more extensive
exploration of circulating levels of PAF in
spontaneous and experimental inflammatory states.
A specific radioimmunoassay for PAF was
developed by Sinai et aL; it appeared to be at least
as sensitive as platelet based assays for PAF, but
was simpler to perform and did not have the
inherent variability of bioassays,
is A commercial
version of this assay was used in the present study.
The blood levels of PAF as measured by RIA in
our control rats, approximately 1.8 ng/ml, were
comparable to those found by Caramelo et aL
It was found that blood and leukocyte levels of
PAF were elevated in most rats injected 10 min
earlier with sufficient immune complexes prepared
in 5 x antigen excess to induce lesions of 3 + to 4
intensity. There was no significant difference in the
number of rats with elevated plasma levels of PAF
at 10 min and 60 min after IC compared with the
control animals. These findings suggest that the
elevated blood values of PAF may reflect the
increase in PAF of circulating leukocytes, most
likely mononuclear cells, because polymorpho-
nuclear leukocytes disappear almost completely
from blood of rats injected 10 min earlier with
IC.
2 The findings also provide direct evidence that
in IC-induced enteropathy, changes in PAF occur
rapidly and do so during the intervals that lesions
are developing in the small intestine.
Based on earlier studies suggesting that PAF was
involved in the induction of lesions, it had been
anticipated that injection of IC might induce a bolus
release of PAF into the circulation. Monocytes in
the circulation or the fixed mononuclear phagocytes
(Kupffer cells) of the liver
2 were considered to be
the most likely source of this anticipated bolus
release of PAF. Failure to find a marked increase of
PAF in plasma under the conditions tested in the
present experiments, suggests that the bolus release
of PAF may not be involved in the induction of
the intestinal lesions provoked by IC, but does not
exclude a role for PAF in the induction of lesions.
The plasma levels of PAF may have failed to
reflect an increase in PAF in this compartment
because it was rapidly cleared by cells bearing PAF
receptors including those of the small intestine.
Another possibility is that the changes in the blood
are paralleled in cells closer to the intestine and that
local release of PAF stimulated by IC is responsible
for the intestinal lesions. Macrophages in the lamina
propria may be one such target for IC stimulation
of local PAF release. The local release of PAF in
close proximity to the putative target cells or tissues
involved in inductions of the intestinal lesions
would avoid the modulating effects of plasma
proteinase inhibitors on PAF production.
16 Another
possibility is that induction of lesions may not
require PAF to be released from any cellular source.
Changes in intracellular levels of PAF in cells (for
example, endothelial cells) at some crucial site might
bring about the vascular changes of IC-induced
enteropathy.
In earlier studies, it was shown that following
the intravenous administration of labelled and
’cold’ IC prepared in 5 x antigen excess,
radioactivity was found primarily in the liver and
small intestine,v In the liver, IC have been shown
to bind to Kupffer cells, hepatocytes and endothelial
cells via Fc receptors.
7 Whether the endothelial
cells of rat small intestine have a similar capacity to
bind IC and to be stimulated, thereby to increase
their synthesis of PAF, remains to be determined.
Human endothelial cells have the capacity to
synthesize and release PAF in response to a variety
of stimuli
8 including the cytokines TNF and IL-1.
Although peak release is not achieved until 15 min
after stimulation, there is considerable release
from endothelial cells by 10 min.
9 Possibly,
endothelial cells of the rat small intestine respond
similarly.
In the rat intestine, platelet activating factor
primarily causes stasis of flow.a In severe lesions of
1C-induced enteropathy, it appears that inflow of
blood into annular segments of the small intestine
is less impaired than outflow leading to severe
congestion with blood, rupture of vessels and
subsequent disruption of the integrity of the villi.
The precise target of PAF, whether it is a blood
vessel wall structure, nerves regulating vasomo-
tion, or both, is not known.
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